Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,956.00    26.00 (1.35%)
Bid:
1,956.00
Ask:
1,956.50
Spread: 0.50 (0.026%)
Market Cap: £78.35b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

15 May 2023 15:30

RNS Number : 4636Z
GSK PLC
15 May 2023
 

GSK plc (the 'Company')

Vesting of 2020 Performance Share Plan Top-Up Award

This notification sets out the vesting details of a "top-up" conditional share award made to the Chief Executive Officer (CEO) on 6 May 2020 under the GSK 2017 Performance Share Plan ('PSP'), following the approval of the 2020 Remuneration Policy at the AGM that year.

This "top-up" PSP award, equivalent to 25% of the CEO's base salary, was made to deliver in aggregate for 2020 an award level of 575% of base salary, increasing her award level from 550%. It was subject to the same business performance conditions as the main 2020 award, with a three-year performance period from 1 January 2020 to 31 December 2022. The main 2020 award vesting was announced on 14 February 2023. The "top-up" award has now vested on the same basis ie 52% vesting 48% lapsed, following the third anniversary of the grant. The vested shares are subject to a further two-year vesting period.

This notification that follows is for the "top-up" award made to the CEO and details the PSP conditional award that vested, including dividends accrued, on 9 May 2023. The balance of the award has lapsed.

The closing price of Ordinary Shares of GSK plc on the vesting date was £14.462.

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The number of Ordinary Shares vesting on the "top-up" award granted in 2020 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

10,729

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

e)

Date of the transaction

2023-05-09

f)

Place of the transaction

 

N/A

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFUFLIEDSESI
Date   Source Headline
4th Feb 20267:00 amRNSFinal Results
2nd Feb 20263:00 pmRNSTotal Voting Rights
26th Jan 20267:00 amRNSEuropean Commission approves Arexvy for adults 18+
20th Jan 20267:05 amRNSGSK to acquire RAPT Therapeutics
20th Jan 20267:00 amRNSAgreement on changes to ViiV minority shareholding
16th Jan 20263:30 pmRNSDirector/PDMR Shareholding
15th Jan 20263:30 pmRNSDirector/PDMR Shareholding
13th Jan 20263:30 pmRNSDirector/PDMR Shareholding
7th Jan 20267:05 amRNSEC approval of Shingrix PFS
7th Jan 20267:00 amRNSPositive phase 3 data for GSK's bepirovirsen
6th Jan 20267:00 amRNSExdensur approved in Japan
5th Jan 20263:30 pmRNSDirector/PDMR Shareholding
5th Jan 20263:00 pmRNSTotal Voting Rights
5th Jan 20267:00 amRNSNucala for adults with COPD approved in China
22nd Dec 20253:30 pmRNSDirector/PDMR Shareholding
22nd Dec 20253:30 pmRNSDirector/PDMR Shareholding
22nd Dec 20257:00 amRNSGSK to lower drug prices and expand access in US
22nd Dec 20257:00 amRNSGSK to lower drug prices and expand access in US
22nd Dec 20257:00 amRNSTransaction in Own Shares
22nd Dec 20257:00 amRNSTransaction in Own Shares
19th Dec 20257:00 amRNSTransaction in Own Shares
19th Dec 20257:00 amRNSTransaction in Own Shares
18th Dec 20257:00 amRNSTransaction in Own Shares
17th Dec 20257:00 amRNSExdensur (depemokimab ulla) approved by US FDA
17th Dec 20257:00 amRNSTransaction in Own Shares
16th Dec 20257:00 amRNSExdensur (depemokimab) UK MHRA approval
16th Dec 20257:00 amRNSTransaction in Own Shares
15th Dec 20257:00 amRNSTransaction in Own Shares
12th Dec 20251:50 pmRNSNucala receives positive CHMP opinion for COPD
12th Dec 20251:41 pmRNSDepemokimab receives positive CHMP opinion
12th Dec 20257:00 amRNSPositive CHMP opinion on Arexvy for all adults 18+
12th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20255:54 pmRNSBlujepa approved in US for gonorrhoea indication
11th Dec 20253:30 pmRNSDirector/PDMR Shareholding
11th Dec 20259:00 amRNSBlock Listing Application
11th Dec 20257:00 amRNSTransaction in Own Shares
10th Dec 20257:00 amRNSGSK'227 US FDA Orphan Drug Designation in SCLC
10th Dec 20257:00 amRNSTransaction in Own Shares
9th Dec 20253:30 pmRNSDirector/PDMR Shareholding
9th Dec 20257:00 amRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
5th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20257:00 amRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
2nd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20253:30 pmRNSDirector/PDMR Shareholding
1st Dec 20253:00 pmRNSTotal Voting Rights
1st Dec 20257:00 amRNSTransaction in Own Shares
28th Nov 20257:00 amRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.